Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964747 | 0.85 | — | — | |
| Formic Acid SCHEMBL19466598 | 0.84 | APLNR (0.35) | APLNR | |
| SCHEMBL23912513 | 0.75 | APLNR (0.48) | APLNR | |
| Formic Acid SCHEMBL28101002 | 0.73 | APLNR (0.35) | APLNR | |
| Formic Acid SCHEMBL20769326 | 0.72 | — | — | |
| SCHEMBL17778117 | 0.70 | APLNR (0.48) | APLNR | |
| SCHEMBL15116677 | 0.70 | APLNR (0.48) | APLNR | |
| SCHEMBL21371877 | 0.70 | APLNR (0.42) | APLNR | |
| SCHEMBL13103443 | 0.69 | APLNR (0.33) | APLNR | |
| Formic Acid SCHEMBL28812219 | 0.69 | MAPT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188088-A1 | COMPOUND AND USE THEREOF | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| EP-4484429-A1 | COMPOUND AND USE THEREOF | OnQuality Pharmaceuticals China Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| CN-105916855-B | Substituted 4, 5, 6, 7-tetrahydropyrazolo [1,5-a ] pyrazine derivatives as casein kinase 1D/E inhibitors | 百时美施贵宝公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-105916855-A | Substituted 4,5,6, 7-tetrahydropyrazolo [1,5-a ] pyrazine derivatives as casein kinase 1D/E inhibitors | 百时美施贵宝公司 | 2016-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188088-A1 | COMPOUND AND USE THEREOF | CYP17A1, CYP11B2, CYP21A2 | APLNR 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.